Related references
Note: Only part of the references are listed.Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Daratumumab for the Treatment of Multiple Myeloma
Torben Plesner et al.
FRONTIERS IN IMMUNOLOGY (2018)
Health-related quality of life in patients with newly diagnosed multiple myeloma who are ineligible for stem cell transplantation: Results from the ALCYONE trial.
Katharine Gries et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma
Xu Steven Xu et al.
ADVANCES IN THERAPY (2018)
Short overview on the current standard of treatment in newly diagnosed multiple myeloma
Ella Willenbacher et al.
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY (2018)
Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma
Xiaoyu Yan et al.
CLINICAL PHARMACOKINETICS (2018)
The evolution of stem-cell transplantation in multiple myeloma
Sarakshi Mahajan et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2018)
Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment
Pamela L. Clemens et al.
CLINICAL PHARMACOKINETICS (2017)
Trends in overall survival and costs of multiple myeloma, 2000-2014
R. Fonseca et al.
LEUKEMIA (2017)
Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma
Hannah A. Blair
DRUGS (2017)
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma
Tineke Casneuf et al.
BLOOD ADVANCES (2017)
Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. Moreau et al.
ANNALS OF ONCOLOGY (2017)
Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma
X. S. Xu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Next-generation multiple myeloma treatment: a pharmacoeconomic perspective
S. Vincent Rajkumar et al.
BLOOD (2016)
CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
Inger S. Nijhof et al.
BLOOD (2016)
Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
Jakub Krejcik et al.
BLOOD (2016)
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference
Christopher McCudden et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2016)
The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcγ Receptor-Mediated Cross-Linking
Marije B. Overdijk et al.
JOURNAL OF IMMUNOLOGY (2016)
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
Shaji Kumar et al.
LANCET ONCOLOGY (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
I. S. Nijhof et al.
LEUKEMIA (2015)
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
Marije B. Overdijk et al.
MABS (2015)
Resolving the daratumumab interference with blood compatibility testing
Claudia I. Chapuy et al.
TRANSFUSION (2015)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
Jesus F. San Miguel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Share Paper
